Literature DB >> 15882941

Quantitative assessment of emphysema distribution in smokers and patients with alpha1-antitrypsin deficiency.

Trine Stavngaard1, Saher B Shaker, Asger Dirksen.   

Abstract

INTRODUCTION: Identification of upper lobe emphysema is mandatory before lung volume reduction surgery (LVRS). Here we introduce a CT-based objective model for describing the distribution of different types of emphysema.
METHODS: Fifty COPD patients were included in the study. Half had alpha1-antitrypsin deficiency (alpha1-COPD) and the rest had smoking-induced emphysema (usual COPD). All patients were scanned 3 times. The relative area of emphysema in each CT slice was plotted against table position, and the cranio-caudal distribution was calculated as the slope of the regression line.
RESULTS: The variation in slopes within a patient was much less than the variation in slopes between patients (P<0.0001). There was a significant difference between slopes in the alpha1-COPD and the usual COPD groups (P<0.0001). In the alpha1-COPD group, 24/25 patients had lower lobe emphysema. In the usual COPD group, 4 patients had upper lope predominance, 5 patients had heterogeneous distributions, and 16 patients had lower lobe predominance.
CONCLUSIONS: The majority of patients with smoking-related emphysema have a homogeneous distribution and lower lobe predominance although not as noticeable as in alpha1-antitrypsin deficiency. An objective and quantitative method for determining the distribution of emphysema should be applied when selecting candidates for LVRS.

Entities:  

Mesh:

Year:  2006        PMID: 15882941     DOI: 10.1016/j.rmed.2005.04.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Sinogram Affirmed Iterative Reconstruction (SAFIRE) versus weighted filtered back projection (WFBP) effects on quantitative measure in the COPDGene 2 test object.

Authors:  J P Sieren; E A Hoffman; M K Fuld; K S Chan; J Guo; J D Newell
Journal:  Med Phys       Date:  2014-09       Impact factor: 4.071

2.  Designing Clinical Trials in "Regular" COPD Versus Alpha-1 Antitrypsin Deficiency-Associated COPD: "More Alike Than Unalike?"

Authors:  James K Stoller
Journal:  Chronic Obstr Pulm Dis       Date:  2022-01-27

3.  Quantitative airway assessment on computed tomography in patients with alpha1-antitrypsin deficiency.

Authors:  Tsuneo Yamashiro; Shin Matsuoka; Raúl San José Estépar; Alejandro Diaz; John D Newell; Robert A Sandhaus; Patricia J Mergo; Mark L Brantly; Sadayuki Murayama; John J Reilly; Hiroto Hatabu; Edwin K Silverman; George R Washko
Journal:  COPD       Date:  2009-12       Impact factor: 2.409

4.  Optimal threshold in CT quantification of emphysema.

Authors:  Zhimin Wang; Suicheng Gu; Joseph K Leader; Shinjini Kundu; John R Tedrow; Frank C Sciurba; David Gur; Jill M Siegfried; Jiantao Pu
Journal:  Eur Radiol       Date:  2012-11-01       Impact factor: 5.315

5.  Emphysema distribution and annual changes in pulmonary function in male patients with chronic obstructive pulmonary disease.

Authors:  Naoya Tanabe; Shigeo Muro; Shiro Tanaka; Susumu Sato; Tsuyoshi Oguma; Hirofumi Kiyokawa; Tamaki Takahashi; Daisuke Kinose; Yuma Hoshino; Takeshi Kubo; Emiko Ogawa; Toyohiro Hirai; Michiaki Mishima
Journal:  Respir Res       Date:  2012-04-18

Review 6.  Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype.

Authors:  Gerard N McElvaney; Robert A Sandhaus; Marc Miravitlles; Gerard M Turino; Niels Seersholm; Marion Wencker; Robert A Stockley
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

7.  High correlation of the response of upper and lower lobe small airway epithelium to smoking.

Authors:  Ben-Gary Harvey; Yael Strulovici-Barel; Thomas L Vincent; Jason G Mezey; Ramya Raviram; Cynthia Gordon; Jacqueline Salit; Ann E Tilley; Augustine Chung; Abraham Sanders; Ronald G Crystal
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.